A reassortant influenza A virus was produced by mating an avian influenza A/Pintail/Alberta/119/79 (H4N6) virus with wild-type human influenza A/Washington/897/80 (H3N2) virus. The avian-human influenza A reassortant virus contained the genes coding for the hemagglutinin and neuraminidase surface antigens of the human influenza wild-type virus and the six other RNA segments (internal genes) of the avian influenza A virus donor. In the lower respiratory tract of squirrel monkeys, this avian-human influenza reassortant virus, like its avian influenza A parent virus, was restricted approximately 100-fold in replication compared with the wild-type human influenza A virus. Despite this restriction of replication, infection of monkeys with the avian-human influenza A reassortant virus induced resistance to wild-type human influenza A virus challenge. In comparison with the wild-type human influenza A virus, the avian-human influenza A reassortant was also fully attenuated when 105i5 to 107-5 50% tissue culture infective doses were administered to susceptible adult volunteers. Attenuation was indicated by a more than 300-fold reduction in virus shedding and lack of reactogenicity. The reassortant virus did not spread to susceptible contacts and could not be isolated from the blood or stools of infected adults. The 50% human infectious dose was 106.2 50% tissue culture infective dose, indicating that this reassortant virus is only slightly less infectious for adults than a similarly derived avian-human influenza A/Washington/80 x A/Mallard/78 reassortant virus. These findings suggest that the avian influenza A/Pintail/79 virus may be a satisfactory donor of attenuating genes for production of live, attenuated avian-human influenza A reassortant virus vaccines.
A novel approach for the development of live influenza A virus vaccines involves the use of an avian influenza A virus as the donor of genes for attenuation of wild-type human influenza A viruses (10) . The avian-human influenza A reassortant virus produced by this method contains the hemagglutinin (HA) and neuraminidase (NA) genes of a human influenza A virus and the other six RNA segments (i.e., internal genes) of an avian influenza A virus. One advantage of this approach is that avian influenza A viruses have evolved over a long period in birds and, thus, contain nucleotide sequences that are significantly different from those of the corresponding genes of human influenza A viruses (2, 13) . Because of this genetic divergence, avian influenza A viruses would be expected to replicate poorly in respiratory epithelial celîs of humans and to retain their attenuation phenotype following such a restricted infection.
Results of previous studies have demonstrated that the avian influenza A/Mallard/New York/6750/78 (H2N2) virus can be used as a donor of its six internal genes to attenuate virulent influenza A viruses for monkeys and humans (4, 6, 10, 14) .
The avian-human influenza A/Mallard/78 x A/Korea/1/82 (H3N2) reassortant virus induced protective immunity in adult volunteers against challenge with the wild-type human influenza A/Korea/l/82 (H3N2) virus (14) .
Several other avian influenza A viruses that exhibit restriction of replication in monkeys were identified in our previous studies (7) . One of these strains, the influenza A/Pintail/Alberta/119/79 (H4N6) virus, replicated slightly more efficiently in the lower respiratory tract of squirrel monkeys than did the A/Mallard/78 strain (7) . This finding suggests that avian-human influenza A virus reassortants derived from the influenza A/Pintail/79 donor virus might be more infectious for humans than reassortants derived from the A/Mallard/78 strain. To answer this question, we produced and characterized a reassortant virus containing the HA and NA genes of the wild-type human A/ Washington/897/80 (H3N2) virus and the six internal genes from the A/Pintail/Alberta/119/79 virus. This reassortant was evaluated for its safety, infectivity, transmissibility, and immunogenicity in monkeys and seronegative adult volunteers. The capacity of this reassortant virus to induce resistance against experimental challenge with wild-type human influenza A virus in monkeys was also assessed.
MATERIALS AND METHODS
Viruses. The isolation and cloning of the avian influenza A/Pintail/Alberta/119/79 (H4N6) virus and wild-type human influenza A/Washington/897/80 (H3N2) virus have been described previously (4, 7) . The isolation and characterization of the avian-human influenza A/Washington/897/80 x A/Mallard/6750/78 reassortant virus used in the current studies on monkeys were also described previously (4) . The wild-type human influenza A/Washington/897/80 virus was previously evaluated in seronegative volunteers (3) ; the data are in-48 CLEMENTS ET AL. cluded herein for the purpose of comparison. The production and characterization of the avian-human influenza A/Washington/897/80 x A/Pintail/Alberta/119/79 reassortant virus were similar to those of the avian-human influenza A/Washington/897/80 x A/Mallard/New York/6750/78 reassortant virus which were reported elsewhere (4). The avianhuman influenza A/Washington/897/80 x A/Pintail/ Alberta/119/79 reassortant virus suspension (Lot E 201) administered to monkeys and humans was grown in the allantoic cavity of specific pathogen-free eggs (SPAFAS, Inc., Norwich, Conn.) by Louis Potash (Flow Laboratories, Inc., McLean, Va.) and had a titer of 108 5 50% tissue culture infectious doses (TCID50) per ml. Virus suspensions were tested for the presence of adventitious agents by Louis Potash; none were found.
Polyacrylamide gel electrophoresis. The parental origin of the genes in the avian-human influenza A/Washington/80 x A/Pintail/79 reassortant virus was determined by comparing the migration of the eight virion RNA segments of the reassortant with those of the two parental viruses by polyacrylamide gel electrophoresis, as described previously for the avian-human influenza A/Washington/80 x A/Mallard/78 reassortant virus (4). Electrophoresis was carried out for 16 to 20 h at 200 V and 5°C on 32-cm gels containing 2.6% polyacrylamide and either 6.0 or 4.5 M urea.
Replication of virus in monkeys. The studies in monkeys were performed as described previously (7, 9) . Briefly, a 107.0 TCID50 of virus in a 0.5-ml inoculum was administered intratracheally to squirrel monkeys. Nasopharyngeal (NP) and rectal swab specimens were collected daily for 10 days. Tracheal lavages were performed on days 2, 4, and 6 after inoculation. The quantity of virus present in each NP swab and tracheal lavage specimen was determined by titration in Madin Darby canine kidney cells, and mean log1o titers were calculated. Serum was collected before and 28 days after virus administration and assayed for hemagglutinationinhibiting (HAI) antibody, using homologous virus as antigen.
Pairs of infected and uninoculated control monkeys were housed together in cages to determine if transmission of reassortant virus occurred. Evidence of infection was sought by sampling contact monkeys for evidence of virus replication and the development of HAI antibody in serum.
To determine if the avian-human influenza A reassortant virus initiated a systemic infection, six monkeys (three males and three females) were sacrificed, two each on days 2, 4, and 8. The following tissues were removed and examined grossly and histologically for pathological changes and for the presence of infectious virus in a 10% (wt/vol) suspension: nasal mucosa, trachea, lung, esophagus, small intestine, colon, kidney, bladder, spleen, liver, thymus, inguinal muscle, myocardium, pancreas, testis, ovary, cerebellum, brain stem, ventricle with ependyma, spinal cord, meninges, were recruited from the University of Maryland and from the Baltimore community. Persons who had a history of influenza vaccination or who were taking medication were not eligible. Those who participated in these studies gave written, informed consent.
The clinical procedures have been detailed previously (6 press). However, unlike the latter virus, the M gene of the influenza A/Pintail/79 virus did not appear to restrict replication. The effect of the internal genes of these two avian viruses on virus replication in squirrel monkeys was assessed in this study by comparing the restriction of replication of reassortants of the two avian donor viruses prepared from the same wild-type human influenza A virus. The previous difference in replication of the two donor viruses in monkeys was not confirmed when their reassortants were compared in the same study. The level of replication of the avian-human influenza A/Washington/80 x A/Pintail/79 and AlWashington/80 x A/Mallard/78 reassortant viruses was comparable in squirrel monkeys, indicating that the internal genes of these two avian viruses imposed a similar restriction on replication of the wild-type human influenza A/Washington/80 virus. However, the avianhuman influenza AlWashington/80 x A/Pintail/79 reassortant virus was slightly less infectious for susceptible adults in this study than was the avian-human reassortant influenza A/Washington/80 x A/Mallard/78 reassortant virus in an earlier study (6) . In seronegative adults, the HID50 for the influenza A/Washington/80 x A/Pintail/79 reassortant was 106-2 TCID50, whereas the HID50 for the influenza A/Washington/80 x A/Mallard/78 reassortant was 105 9 TCID50. Each of these reassortants stimulated an immunologic response in at least 80% of seronegative adults to whom were administered 20 to 100 HID50 of virus intranasally (3, 6) .
Protective efficacy of the avian-human influenza A/Washington/80 x AlPintail/79 reassortant virus was demonstrated by experimental challenge of squirrel monkeys with wildtype human influenza A/Washington/80 virus. Significant resistance to replication of wild-type virus was observed in the nasopharynx and trachea of monkeys previously infected with this reassortant. There was also a 50% reduction in frequency of infection in the vaccinated monkeys compared with that in unvaccinated placebo controls. These results are encouraging and suggest that reassortants derived from the avian influenza A/Pintail/79 donor virus should be evaluated further for their suitability for use in live attenuated influenza A virus vaccines.
